# Study to Assess PK, Safety and Tolerability in Patients With DM and CKD

> **NCT03795389** · PHASE1 · COMPLETED · sponsor: **DiaMedica Therapeutics Inc** · enrollment: 33 (actual)

## Conditions studied

- Chronic Kidney Disease
- Chronic Kidney Disease, Stage 3 (Moderate)
- Chronic Kidney Disease, Stage 4 (Severe)
- Diabetes

## Interventions

- **DRUG:** DM199

## Key facts

- **NCT ID:** NCT03795389
- **Lead sponsor:** DiaMedica Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-12
- **Primary completion:** 2019-07-21
- **Final completion:** 2019-07-21
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2021-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03795389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03795389, "Study to Assess PK, Safety and Tolerability in Patients With DM and CKD". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03795389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*